<DOC>
	<DOCNO>NCT01101594</DOCNO>
	<brief_summary>This study Ph I trial test safety study drug , hLL1-DOX different dose level patient recurrent multiple myeloma . HLL1 also know milatuzumab attach doxorubicin clinical trial .</brief_summary>
	<brief_title>A Study hLL1-DOX ( Milatuzumab-Doxorubicin Antibody-Drug Conjugate ) Patients With Multiple Myeloma</brief_title>
	<detailed_description>In clinical research trial , hLL1-DOX administer day 1 , 4 , 8 11 . This treatment cycle repeat every 3 week long patient continue tolerate , maximum 8 treatment cycle ( approximately 6 month ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Able provide sign , informed consent ; Male female , &gt; /= 18 year old ; Multiple myeloma one criterion measurable disease ( serum M protein &gt; 0.5 gm/dl , urinary M protein excretion &gt; 200 mg/24 hour , serum free light chain measurement &gt; 20 mg/dl , ) ; Refractory relapse least two prior standard systemic antimyeloma treatment regimens one must include either thalidomide , lenalidomide bortezomib ; Adequate performance status ( Karnofsky Scale &gt; /= 70 % ) ; Life expectancy least 6 month ; Adequate cardiac function : MUGA scan 2DECHO LVEF 55 % , EKG medically relevant arrhythmia uncontrolled medication ; Adequate hematologic status within 2 week study drug administration : Hemoglobin &gt; /=8.0 g/dL platelet &gt; /=75,000/mm3 ( without transfusion hematologic support within 7 day laboratory test ) White blood count ( WBC ) &gt; /= 2,000/mm3and absolute neutrophil count ( ANC ) &gt; /=1,500/mm3 ( without use colony stimulate factor within 7 day laboratory test ) ; Adequate renal function : serum creatinine &lt; /+ 2.5 mg/mL ; Adequate hepatic function AST ALT &lt; /= 2.5 x ULN Total bilirubin &lt; /= 1.5 x ULN 1 . Pregnant lactating woman . Women childbearing potential must negative pregnancy test Pregnancy testing require postmenopausal surgically sterilized woman ; Patients eligible stem cell transplant . Women childbearing potential fertile men practice unwilling practice birth control enrol study least 12 week last hLL1dox infusion ; Prior local radiotherapy within 14 day ; chemotherapy kyphoplasty within 21 day , immunotherapy , plasmapheresis , major surgery within 28 day ; prior stem cell transplant within 12 week . Must persistent â‰¥ Grade 2 toxicity prior treatment ; Prior treatment therapeutic agent MM investigational agent within 4 week , unless study , agree Sponsor ; A history allergic adverse reaction anthracycline/anthracenedione agent ; Cumulative lifetime anthracycline/anthracenedione exposure exceed 300 mg/m2 ( include daunorubicin , idarubicin , epirubicin mitoxantrone ) ; Known HIV positive , prior hepatitis B C infection ; Any history clinically significant autoimmune disease ( e.g. , collagen vascular disorder , autoimmune hepatitis , Coombs positive anemia/thrombocytopenia , etc . ) Prior history mediastinal pericardial external beam radiation therapy . Prior history treatment trastuzumab , unless discuss agree Medical Monitor . Systemic infection require antiinfectives within 7 day first dose study drug ; Substance abuse concurrent medical condition , Investigator 's opinion , could confound study interpretation affect patient 's ability tolerate complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Treatment</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed , refractory multiple myeloma</keyword>
</DOC>